Hazardous Waste Site Health Assessment Team

March 9, 2020 | 129 views

We look into whether hazardous waste sites cause health risks. A hazardous waste site can be any place where chemicals have gotten into the air, water and soil. Former landfills and industrial plants, even areas where crops have been grown, can be hazardous waste sites.

Spotlight

Cerenis Therapeutics

Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001). CER-001 has successfully completed Phase I. The product is designed to rapidly regress atherosclerotic plaque among patients at high risk of cardiovascular events. It is based on Cerenis’ multiple breakthroughs in the science of HDL, which have allowed the identification and development of highly potent and pure HDL particles.

OTHER ARTICLES
Chemical Technology

Demographics are reshaping petrochemicals trade flows, investment patterns and demand

Article | July 14, 2022

TEN YEARS AGO, fellowblogger Paul Hodgesand Ifirst highlighted the leading rolethat changing demographics would play in reshaping petrochemicals supply and demand. We have been emphasising the importance of demographics ever since. Demographics have, of course, always been a critical shaper of economies throughout human history. But during the last 70 years, there have been such major changes in demographics that the study of demographics must be at the very heart of your company’s strategy. The Babyboomer generation in the West led to a surge in demand as the rapid increase in babies born in the 1950s and early 1960s joined the workforce from the 1970s onwards. This helps explain high levels of inflation during that decade because too much demand was chasing too little supply. Another driver of inflation was the Middle East embargos against oil exports to the West because of the West’s support for Israel. Then came the 1990s and first the integration of Eastern Europe into the global economy. This helped dampen inflationary pressures because of the plentiful supply of workers in the east willing to work for low wages in export-focused factories. This reduced the cost of finished goods in the West. Next came Deng Xiaoping’s critically important“southern tour”in the early 1990s and China’s gradual integration into the global economy. China increasingly leveraged its very youthful population to again make cheap goods to export to the West. Hundreds of millions of young people were willing to migrate from the countryside to China’s coastal cities to work in export-focused manufacturing plants. The world began to talk about the “China price” and how it was further depressing global inflation.

Read More
Chemical Management

The Future of Supply Chain Management for Chemical Companies

Article | July 8, 2022

Individual consumers expect tailored products and services. Color, size, quantity, payment method, and delivery channel options abound. The chemical sector is also now following this suit of action. The global chemicals supply chain has grown steadily for three decades. Chemical businesses are improving their supply chain capabilities to handle complexity and meet client demands. This includes implementing advanced data-driven and cloud-based technologies that enable faster, more flexible, and tailored customer interactions. Areas of innovation for chemical companies Living Segmentation Living segmentation can help chemical businesses better serve clients and satisfy their expectations. This entails adapting supply chain capabilities to each customer's needs. Asset-light Network An asset-light network involves developing an ecosystem of partners to add capabilities and value to your supply chain beyond standard co-manufacturing, co-packing, and third-party or last-mile logistics providers. In addition, it should include technology partners that help chemical businesses innovate and be adaptable. Data and Applied Intelligence Improving speed, agility, and efficiency in global supply chains demands comprehensive visibility and the correct information. Data provides visibility and insights. The key to providing excellent customer service is gathering the appropriate data and using it strategically to get important insight. The industry generates a ton of data, which is excellent news. In response to last year's supply chain delays, corporations are building supply chains with geographically spread shipping/supplier choices. Real-time visibility and enhanced analytics can be used to track delays by providing revised ETAs and analyzing downstream implications. Data-driven insights can alert organizations of a delay almost immediately and help them acquire raw materials from another supplier to reduce the domino impact downstream. Chemical businesses must rethink their supply chains to implement living segmentation, asset-light networks, data, and AI.

Read More
Chemical Technology

Energy portfolio restructuring: Charting the future

Article | June 6, 2022

Consumer needs and preferences in the energy industry are evolving. Environmental, social and governance (ESG) concerns are becoming more acute—inspiring action and shifting value towards low-carbon solutions. These trends accelerated in 2020 and for the first time, market capitalization of leading low-carbon solutions companies began to overtake those of oil and gas (O&G) majors. This is despite the majors laying out energy transition strategies, setting low carbon energy targets and generating higher revenues by an order of magnitude.1 In response to this radically changing landscape, energy companies are charting divergent courses for their futures. Some continue to bet on their ability to generate returns from the O&G value chain. They are focusing on growing margins and lowering carbon intensity. Others are supplementing their capabilities with low-carbon energy solutions or exiting hydrocarbons altogether. This blog focuses on the path forward for the energy majors in Europe who are betting big on diversification.

Read More
Chemical Management

Southeast polyolefins demand growth could be negative again in 2021

Article | July 13, 2021

BEFORE the pandemic, GDP growth rates in the developing world were always higher than in developed economies.And because developing economies had much lower levels of petrochemicals consumption than their rich counterparts, it meant that the multiples over GDP were higher than in the rich word, where consumption was pretty much saturated. For instance, polyethylene (PE) demand in a developed country such as Germany might have grown at 0.3% times GDP whereas in Indonesia the growth could have been one or more times higher than the rate of growth in GDP.But as The Economist wrote in this 11 July article: “In 2021 the poorest countries, which are desperately short of vaccines, are forecast to grow more slowly than rich countries for only the third time in 25 years.” Might the multiples over GDP growth also be adversely affected in the developing world, trending lower than the historic norms? They will almost certainly remain higher than the rich countries. But here is the thing: as millions more people are pushed back into extreme poverty by the pandemic or are denied the opportunity to achieve middle-income status, I believe that developing-world multiples may well decline.Escaping extreme poverty means being able to, say, afford a whole bottle of shampoo for the first time rather than a single-serve sachet, thereby raising per capita polymers consumption.

Read More

Spotlight

Cerenis Therapeutics

Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001). CER-001 has successfully completed Phase I. The product is designed to rapidly regress atherosclerotic plaque among patients at high risk of cardiovascular events. It is based on Cerenis’ multiple breakthroughs in the science of HDL, which have allowed the identification and development of highly potent and pure HDL particles.

Related News

NGOs file suit over transparency of TSCA new chemicals programme

Chemical Watch | March 18, 2020

A coalition of NGOs has sued the US EPA over an alleged lack of transparency in the TSCA new chemicals programme, which "thwart[s] the ability of the public to be informed and to provide input". According to a complaint filed by five environmental nonprofits in federal court today, the EPA has operated its TSCA premanufacture review process in a "black box, denying the public information to which they are legally entitled". Having access to timely information, they contend, is necessary to ensure the members they represent "are able to provide input on the potential risks of new chemicals and the need for protections from those risks prior to completion of EPA’s reviews." And they therefore have asked the court to ensure that the EPA complies with TSCA’s disclosure provisions, including by requiring that it:

Read More

ACC to Trump, governors: Keep chemical industry going during coronavirus crisis

S&P Global | March 18, 2020

The US chemical industry's trade group told President Donald Trump and state governors this week that its sector must maintain operations as the coronavirus outbreak spreads to ensure supply of chemicals needed for disinfectants, plastics for food preservation and medical equipment, and staples like diapers and soap. "The role of chemistry is particularly important today, as chemicals enable countless products that will be needed to support good hygiene and treat those who are infected with the coronavirus in the weeks and months ahead," American Chemistry Council President and CEO Chris Jahn said in a letter to Trump and governors late Tuesday. Efforts to hinder the spread of coronavirus have included cancellations of major sporting events, concerts, conferences, parades, and other large gatherings, as well as closures of bars and limiting restaurants to takeout and deliveries. Companies have increasingly sent employees to work from their homes, while hospitals, grocery stores, and drug stores work to keep up with demand for care and products.

Read More

How small chemical company leaders are dealing with the coronavirus

C&EN | March 17, 2020

As measures to contain the coronavirus—SARS-CoV-2—sweep across the US, the heads of privately owned chemical and instrument companies find themselves in uncharted territory trying to keep their companies going and their employees safe. C&EN reached out to CEOs of several such firms to learn what they are doing to keep business moving forward. We heard stories about setbacks, as expected supplies didn’t come through, but also small triumphs, as needed safety equipment was finally found. Overall, these leaders are keeping a close eye on supplies while planning for the real possibility that orders will drop in the coming months. Keeping staff healthy and maintaining continuity in customer service are the top priorities at Boron Specialties. “We are a pretty small facility, seven people &on-site&, so as best as we can we’re isolating,” CEO and founder Beth Bosley says.

Read More

NGOs file suit over transparency of TSCA new chemicals programme

Chemical Watch | March 18, 2020

A coalition of NGOs has sued the US EPA over an alleged lack of transparency in the TSCA new chemicals programme, which "thwart[s] the ability of the public to be informed and to provide input". According to a complaint filed by five environmental nonprofits in federal court today, the EPA has operated its TSCA premanufacture review process in a "black box, denying the public information to which they are legally entitled". Having access to timely information, they contend, is necessary to ensure the members they represent "are able to provide input on the potential risks of new chemicals and the need for protections from those risks prior to completion of EPA’s reviews." And they therefore have asked the court to ensure that the EPA complies with TSCA’s disclosure provisions, including by requiring that it:

Read More

ACC to Trump, governors: Keep chemical industry going during coronavirus crisis

S&P Global | March 18, 2020

The US chemical industry's trade group told President Donald Trump and state governors this week that its sector must maintain operations as the coronavirus outbreak spreads to ensure supply of chemicals needed for disinfectants, plastics for food preservation and medical equipment, and staples like diapers and soap. "The role of chemistry is particularly important today, as chemicals enable countless products that will be needed to support good hygiene and treat those who are infected with the coronavirus in the weeks and months ahead," American Chemistry Council President and CEO Chris Jahn said in a letter to Trump and governors late Tuesday. Efforts to hinder the spread of coronavirus have included cancellations of major sporting events, concerts, conferences, parades, and other large gatherings, as well as closures of bars and limiting restaurants to takeout and deliveries. Companies have increasingly sent employees to work from their homes, while hospitals, grocery stores, and drug stores work to keep up with demand for care and products.

Read More

How small chemical company leaders are dealing with the coronavirus

C&EN | March 17, 2020

As measures to contain the coronavirus—SARS-CoV-2—sweep across the US, the heads of privately owned chemical and instrument companies find themselves in uncharted territory trying to keep their companies going and their employees safe. C&EN reached out to CEOs of several such firms to learn what they are doing to keep business moving forward. We heard stories about setbacks, as expected supplies didn’t come through, but also small triumphs, as needed safety equipment was finally found. Overall, these leaders are keeping a close eye on supplies while planning for the real possibility that orders will drop in the coming months. Keeping staff healthy and maintaining continuity in customer service are the top priorities at Boron Specialties. “We are a pretty small facility, seven people &on-site&, so as best as we can we’re isolating,” CEO and founder Beth Bosley says.

Read More

Events